Radioimmunotherapy of Non-Hodgkin’s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response? - Sharkey, RM; Brenner, A; Burton, J (J Nucl Med, 2003)